Emerging immunotargets in bladder cancer

Francesco Massari, Chiara Ciccarese, Nuno Vau, Matteo Santoni, Rodolfo Montironi, Liang Cheng, Rita C. Marques, Marina Scarpelli, Jorge Fonseca, Marc R. Matrana, Moch Holger, Stefano Cascinu, Giampaolo Tortora, Antonio Lopez-Beltran

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.

Original languageEnglish (US)
Pages (from-to)757-770
Number of pages14
JournalCurrent Drug Targets
Volume17
Issue number7
StatePublished - Jun 1 2016

    Fingerprint

Keywords

  • Bladder cancer
  • Clinical trials
  • Immunotherapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Massari, F., Ciccarese, C., Vau, N., Santoni, M., Montironi, R., Cheng, L., Marques, R. C., Scarpelli, M., Fonseca, J., Matrana, M. R., Holger, M., Cascinu, S., Tortora, G., & Lopez-Beltran, A. (2016). Emerging immunotargets in bladder cancer. Current Drug Targets, 17(7), 757-770.